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(HAPO) study.3,4 Fifteen institutional review boards 
approved our protocol, and none rejected the trial 
on ethical grounds. In addition, an independent 
data and safety monitoring committee regularly 
reviewed the trial. Some participants would not 
even have met the criteria for gestational diabetes 
(more evidence of clinical equipoise). We strongly 
disagree with an assertion that we unnecessarily 
exposed participants to harm. Randomized trials 
are necessary provided that there is sufficient un-
certainty and that the results will resolve the dis-
pute among physicians, which was the case for the 
treatment of mild gestational diabetes.5 We agree 
that our results may encourage previously reluctant 
physicians to treat gestational diabetes, but such 
treatment is now supported by evidence from a 
clinical trial rather than by expert opinion alone.
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Dectin-1 Deficiency and Mucocutaneous Fungal Infections
To the Editor: Mucocutaneous candidiasis is 
commonly seen in persons with deficient T-cell–
mediated immunity, including newborn infants, 
patients with the acquired immunodeficiency syn-
drome, and those with genetically defined pri-
mary T-cell deficiencies.1 In their Brief Report 
about human dectin-1 deficiency and mucocuta-
neous fungal infections, Ferwerda et al. (Oct. 29 
issue)2 suggest that chronic mucocutaneous can-
didiasis may also be caused by a genetic defect of 
the β-glucan receptor dectin-1. However, their 
data should be interpreted with caution. First, 
they provide no information about how dectin-1 
deficiency impairs overall T-cell–dependent mu-
cosal immunity against candida. Second, they 
suggest that the lack of invasive fungal infection 
in dectin-1–deficient patients may be attributed to 
the normal phagocytosis and killing of candida 
by granulocytes. This explanation sounds reason-
able but conflicts with observations of invasive 
microbial disease in patients with other, recently 
described innate immune deficiencies.3,4 Finally, 
it is difficult to define the precise immunologic 
role of dectin-1 in immunity to candida in light 
of the demonstration by Saijo et al.5 that dectin-1 
may not actually be required for host defense 
against Candida albicans.
László Maródi, M.D. 
Melinda Erdös, M.D.
University of Debrecen 
Debrecen, Hungary 
lmarodi@dote.hu
No potential conflict of interest relevant to this letter was re-
ported.
Maródi L. Local and systemic host defense mechanisms 1. 
against Candida: immunopathology of candidal infections. Pe-
diatr Infect Dis J 1997;16:795-801.
Ferwerda B, Ferwerda G, Plantinga TS, et al. Human dectin-1 2. 
deficiency and mucocutaneous fungal infections. N Engl J Med 
2009;361:1760-7.
Ku CL, Picard C, Erdös M, et al. IRAK-4 and NEMO muta-3. 
tions in otherwise healthy children with recurrent invasive 
pneumococcal disease. J Med Genet 2007;44:16-23.
von Bernuth H, Picard C, Jin Z, et al. Pyogenic bacterial in-4. 
fections in humans with MyD88 deficiency. Science 2008;321: 
691-6.
Saijo S, Fujikado N, Furuta T, et al. Dectin-1 is required for 5. 
host defense against Pneumocystis carinii but not against Can-
dida albicans. Nat Immunol 2007;8:39-46.
The Authors Reply: In response to Maródi and 
Erdös: T-cell–derived immunity, and especially 
responses of type 17 helper T cells (Th17), are 
crucial for mucosal antifungal defense.1,2 Our 
report describes deficient Th17-cell responses in 
patients with dectin-1 deficiency,3 and a similar 
defect has been reported in persons with defective 
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CARD9, the caspase recruitment domain–contain-
ing protein 9.3 The fact that dectin-1 deficiency 
increases susceptibility to mucocutaneous, but not 
systemic, fungal infections stresses the specific 
role that dectin-1 may have in mucosal antifun-
gal host defense. This is not in conflict with a 
role of NEMO (the inhibitor of kappa light poly-
peptide gene enhancer in B cells, kinase gamma), 
IRAK-4 (the interleukin-1 receptor–associated ki-
nase 4), or MyD88 (the protein encoded by myeloid 
differentiation primary response gene 88) for the 
host defense against systemic bacterial or fungal 
infections, since these are adaptor molecules 
specific for toll-like receptors, a different class of 
pattern-recognition receptors.4 The suggestion by 
Saijo et al.5 in their study that dectin-1 is not in-
volved in the host defense against systemic can-
didiasis in mice reinforces the conclusion that 
dectin-1 may be specific for mucosal antifungal 
defense.
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Taxing Sugar-Sweetened Beverages
To the Editor: Brownell et al. (Oct. 15 issue)1 
provide support for a tax on sugar-sweetened 
beverages in part by citing the results of long-
term, randomized, controlled trials. They cite a 
report of a 1-year trial involving students 7 to 11 
years of age that showed a lower incidence of 
obesity in the dietary intervention group, although 
the difference in body-mass index was not sig-
nificant.2 Follow-up 2 years after completion of 
the trial showed that the difference in the inci-
dence of obesity was not sustained.3 This dietary 
intervention apparently only had a transient ef-
fect without affecting the long-term propensity 
for obesity. None of the three other long-term, 
randomized, controlled trials cited in the article 
met their primary end points; an analysis of a 
different subgroup within each trial was made in 
an attempt to show some benefit.
The essential failure of these trials should give 
us pause. Before assigning blame for the obesity 
epidemic, we should have clinical evidence that 
an intervention to reduce the consumption of 
sugar-sweetened beverages is effective in achiev-
ing this goal, is either more effective or additive to 
the effect of other proven dietary therapies, and 
will reduce the long-term propensity for obesity.
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To the Editor: Although their intent is unques-
tionably noble, Brownell and coauthors do not 
produce an economic rationale for a soda tax; 
they merely present one side of the economic 
equation (cost–harm) without consideration of its 
usefulness. To maintain liberty, we defer to indi-
vidual persons to balance the cost–utility equa-
tion. However, the authors point to market fail-
ure as a justification for intervention. Their first 
two rationales involve the argument that the pop-
ulation lacks the capacity to make free economic 
decisions. In attempting to restrict peoples’ lib-
erty, the onus is on the authors to convincingly 
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